Jasper Therapeutics Inc.

NASDAQ: JSPR · Real-Time Price · USD
3.07
0.04 (1.32%)
At close: Aug 15, 2025, 3:59 PM
3.05
-0.65%
After-hours: Aug 15, 2025, 06:15 PM EDT

Jasper Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
1.17M 1.17M 1.17M 2.05M 2.05M 2.05M 2.05M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
1.67M 1.71M 1.72M 1.21M 945K 1.02M 1.11M 1.39M 1.48M 1.41M 1.31M 1.17M 1.15M 838K 566K 336K n/a n/a
Gross Profit
-491K -532K -541K -1.21M -945K -1.02M -1.11M -1.39M -1.48M -1.41M -1.31M -1.17M -1.15M -838K -566K -336K n/a n/a
Operating Income
-94.05M -82.97M -76.24M -68.68M -68.15M -69.99M -68.86M -64.88M -58.23M -52.37M -51.2M -49.53M -46.9M -43.36M -36.83M -30.71M -26.64M -24.23M
Interest Income
3.28M 4.3M 5.06M 5.35M 5.5M 5.49M 5.2M 3.96M 2.79M 1.45M 353K 353K 94K 2K n/a n/a n/a n/a
Pretax Income
-90.92M -78.78M -71.27M -63.53M -62.44M -63.93M -64.47M -61.09M -55.41M -49.74M -37.69M -33.53M -25.08M -23.09M -30.64M -31.57M -38.98M -39.99M
Net Income
-64.2M -78.78M -71.27M -63.53M -62.44M -63.93M -64.47M -61.09M -55.41M -49.74M -37.69M -33.53M -25.08M -23.09M -30.64M -31.57M -38.98M -39.99M
Selling & General & Admin
22.47M 21.29M 20.13M 18.51M 17.59M 17.42M 17.08M 17.65M 16.82M 16.12M 16.57M 15.53M 14.73M 14.17M 11.41M 9.3M 7.89M 5.87M
Research & Development
71.58M 61.68M 55.82M 49.88M 50.28M 52.28M 51.78M 47.23M 41.41M 36.24M 34.63M 34M 32.17M 29.19M 25.42M 21.41M 18.74M 18.36M
Other Expenses
n/a n/a n/a n/a n/a -109K -179K 122K 122K 320K 318K 17K 17K -68K 5K 5K 5K 1K
Operating Expenses
94.05M 82.97M 75.95M 68.39M 67.86M 69.7M 68.86M 64.88M 58.23M 52.37M 51.2M 49.53M 46.9M 43.36M 36.83M 30.71M 26.64M 24.23M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 9K 9K 3.51M 7.54M 7.64M 7.64M
Selling & Marketing Expenses
n/a n/a -288K -288K -288K -288K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
94.05M 82.97M 76.24M 68.68M 68.15M 69.99M 68.86M 64.88M 58.23M 52.37M 51.2M 49.53M 46.9M 43.36M 36.83M 30.71M 26.64M 24.23M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -4K -4K -4K -4K 1.2K
Shares Outstanding (Basic)
15.02M 15.02M 14.59M 15M 14.99M 13.34M 11.04M 10.97M 10.92M 8.82M 3.67M 36.57M 36.4M 36.31B 4.97M 496.62K 10M 37.82M
Shares Outstanding (Diluted)
15.33M 15.02M 14.59M 15M 14.99M 13.34M 11.04M 10.97M 10.92M 8.82M 3.67M 3.66M 3.64M 3.63M 4.97M 4.97M 10M 37.82M
EPS (Basic)
-6.04 -5.27 -4.89 -4.74 -5.1 -5.6 -6.19 -8.29 -9.89 -11.32 -10.3 -8.52 -12.22 -9.54 -9.2 -7.64 -1.03 -16.89
EPS (Diluted)
-6.04 -5.27 -4.89 -4.74 -5.1 -5.6 -6.37 -8.47 -10.07 -11.5 -10.3 -8.52 -12.22 -9.54 -9.2 -7.64 -1.03 -16.87
EBITDA
-89.51M -78.13M -71.39M -67.27M -67.01M -68.86M -67.75M -63.78M -57.14M -51.33M -50.22M -51.81M -42.64M -39.28M -32.95M -17.98M -20.72M -12.33M
EBIT
-90.22M -79.49M -72.76M -68.68M -68.15M -69.99M -68.86M -64.88M -58.23M -52.37M -51.2M -52.71M -43.4M -39.86M -33.33M -24.12M -31.43M -29.03M
Depreciation & Amortization
1.32M 1.36M 1.37M 1.41M 1.15M 1.12M 1.21M 1.29M 1.37M 1.32M 1.16M 986K 964K 775K 581K 6.34M 12.02M 18M